Opinion|Videos|July 3, 2024
The EMBARK trial investigating enzalutamide in NM CSPC
Prostate cancer experts analyze the EMBARK trial, emphasizing the potential impact of an androgen receptor inhibitor in the treatment of non-metastatic castration-sensitive prostate cancer.
Advertisement
Episodes in this series
- Dr. Efstathiou asks Dr. Freedland: Enzalutamide is currently the only androgen receptor inhibitor approved for non-metastatic CSPC. Can you summarize the key data from the EMBARK trial supporting its use in this setting?
- Please comment of the high risk study population evaluated in the EMBARK trial
- What were the primary endpoints and efficacy findings from the EMBARK trial? Please also comment on your impressions of the monotherapy arm.
- What are your impressions of the safety data from EMBARK?
Advertisement
Related to this article
The FDA has approved lutetium Lu 177 vipivotide tetraxetan plus an ARPI for PSMA-positive metastatic hormone-sensitive prostate cancer.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualizing ARPI-based therapy in advanced prostate cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
OS Wins, New Approvals, and Practice-Changing Data: Breaking Down the Biggest NSCLC News From ASCO 2026
2
FDA Approves Rituximab Biosimilar for Hematologic Malignancies
3
Emerging Maintenance Strategies May be the Key to Extending Survival in ES-SCLC
4
Phase 1 Data Set the Stage for Further Exploration of Cevostamab in R/R Myeloma
5